MedTrace Logo

Population Pharmacokinetics of Tacrolimus in Nephrotic Syndrome

NCT04045171 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-08-05

No results posted yet for this study

Summary

This study will use a multi-center, prospective design, with a "Real World Study" model, to include 200 patients with nephrotic syndrome. based on the Population Pharmacokinetics (PPK) model, it will study genotype and clinical factors in patients with nephrotic syndrome, to explore the Pharmacokinetics/ Pharmacodynamics (PK/PD) relationship of Tacrolimus in patients with nephrotic syndrome, and develop an optimal medication regimen.

Conditions

Interventions

DRUG

Tacrolimus

Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months

Sponsors & Collaborators

  • Hunan Provincial People's Hospital

    collaborator OTHER

  • ZhuZhou Central Hospital

    collaborator OTHER

  • First People's Hospital of Chenzhou

    collaborator OTHER

  • The Third Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • ZHIJUN HUANG, Dr. · The Third Xiangya Hospital of Central South University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-10
Primary Completion
2020-07-31
Completion
2020-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04045171 on ClinicalTrials.gov